Login to Your Account

Avanir's $40M Public Offering to Aid Final Push for Zenvia

By Tiffany Turner

Friday, March 28, 2008
Avanir Pharmaceuticals has taken a step to push Zenvia, its late-stage investigational drug for pseudobulbar affect (PBA) further along the regulatory pipeline. The Aliso Viejo, Calif.-based company reached out to investors Wednesday with a $40 million registered direct offering to complete development of the drug. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription